Skip to main content

Table 1 Clinical characteristics of the patients that received IVT treatment

From: Intravenous thrombolysis for acute ischemic stroke during two COVID-19 outbreaks in China: Wuhan pandemic and Beijing pandemic

 

Overall (n = 440)

Pre-COVID-19 (n = 258)

Wuhan pandemic (n = 55)

Post-Wuhan (n = 32)

Beijing pandemic (n = 35)

Post-Beijing (n = 60)

P value

Age (years), median [IQR]

63 [56–71]

62 [55–69]

65 [57–73]

63 [56–72]

67 [56–77]

65 [58–74]

.072

Age ≥ 80 years, n(%)

45 (10.2)

18 (7.0)

5 (9.1)

5 (15.6)

5 (14.3)

12 (20.0)

.043

Male, n(%)

310 (70.5)

179 (69.4)

39 (70.9)

22 (68.8)

29 (82.9)

41 (68.3)

.573

Transferred, n(%)

49 (11.1)

32 (12.4)

5 (9.1)

5 (15.6)

2 (5.7)

5 (8.3)

.559

Bridging MT, n(%)

43 (9.8)

22 (8.5)

5 (9.1)

0 (0.0)

9 (25.7)

7 (11.7)

.006

Onset-to-arrival time (min), median [IQR]

114.50 [73.00–165.00]

120.00 [70.75–169.25]

100.00 [70.50–149.50]

117.50 [73.25–138.75]

110.00 [75.50–185.00]

120.50 [77.25–164.75]

.556

Arrival-to-CT time (min), median [IQR]

16.00 [10.00–24.00]

15.00 [8.00–21.00]

17.00 [11.00–22.75]

16.00 [10.00–30.00]

25.00 [16.00–33.00]

20.00 [13.75–28.00]

 < .001

CT-to-tPA (min), median [IQR]

29.00 [21.00–51.25]

29.00 [20.25–52.00]

31.00 [21.50–52.00]

35.00 [23.50–106.25]

30.00 [23.50–45.00]

26.50 [19.75–41.00]

.372

DNT time (min), median [IQR]

45.00 [35.00–61.00]

43.00 [33.00–58.00]

49.00 [35.00–64.00]

48.50 [39.75–70.50]

55.00 [45.50–70.00]

47.00 [38.00–60.50]

.016

DNT ≤ 60 min, n(%)

325 (73.9)

200 (77.5)

38 (69.1)

20 (62.5)

22 (62.9)

45 (75.0)

.146

Onset-to-tPA (min), median [IQR]

167.50 [126.75-220.50]

166.50 [125.25–218.00]

155.00 [123.00–204.50]

170.00 [132.25, 219.25]

169.00 [132.50–244.00]

174.50 [126.00–227.00]

.597

Pre-mRS score, n(%)

      

.155

0

291 (76.6)

179 (75.2)

39 (88.6)

20 (74.1)

19 (79.2)

34 (72.3)

 

1

44 (11.6)

29 (12.2)

0 (0.0)

3 (11.1)

4 (16.7)

8 (17.0)

 

2

21 (5.5)

14 (5.9)

2 (4.5)

1 (3.7)

0 (0.0)

4 (8.5)

 

3

14 (3.7)

7 (2.9)

3 (6.8)

2 (7.4)

1 (4.2)

1 (2.1)

 

4

9 (2.4)

8 (3.4)

0 (0.0)

1 (3.7)

0 (0.0)

0 (0.0)

 

5

1 (0.3)

1 (0.4)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

Admission NIHSS score, median [IQR]

5 [3-11]

5 [3-9]

8 [4-12]

6 [4-10]

7 [5-14]

9 [4-12]

 < .001

NIHSS score ≤ 3, n (%)

126 (28.6)

91 (35.3)

9 (16.4)

8 (25.0)

6 (17.1)

12 (20.0)

.006

NIHSS score ≤ 5, n (%)

227 (51.6)

148 (57.4)

25 (45.5)

16 (50.0)

15 (42.9)

23 (38.3)

.048

NIHSS score after tPA injection, median [IQR]

3 [1-7]

3 [1–6]

5 [2–10]

3 [1–7]

5 [2–14]

3 [1–9]

.013

NIHSS score at 2 h after tPA injection, median [IQR]

4 [1–7]

2 [1–6]

3 [2–5]

4 [1–8]

4 [3, 13]

4 [1–11]

.411

NIHSS score at 24 h after tPA injection, median [IQR]

3 [1–7]

2 [1–5]

3 [1–10]

4 [0–6]

6 [3–12]

3 [1–9]

.275

NIHSS reduction at 24 h, (median [IQR])

2 [0–4]

2 [0–4]

3 [0–4]

2 [0–3]

2 [-1–6]

2 [0–5]

.915

Hypertension, n(%)

225 (51.1)

138 (53.5)

29 (52.7)

18 (56.2)

13 (37.1)

27 (45.0)

.330

Atrial fibrillation, n(%)

38 (8.6)

25 (9.7)

5 (9.1)

1 (3.1)

1 (2.9)

6 (10.0)

.398

Diabetes, n(%)

101 (23.0)

62 (24.0)

10 (18.2)

11 (34.4)

3 (8.6)

15 (25.0)

.113

Hyperlipidemia, n(%)

48 (10.9)

34 (13.2)

4 (7.3)

4 (12.5)

3 (8.6)

3 (5.0)

.281

Prior stroke, n(%)

85 (19.3)

57 (22.1)

8 (14.5)

5 (15.6)

5 (14.3)

10 (16.7)

.512

History of antiplatelet therapy, n(%)

60 (13.6)

30 (11.6)

6 (10.9)

6 (18.8)

6 (17.1)

12 (20.0)

.389

History of statin, n(%)

47 (10.7)

26 (10.1)

5 (9.1)

6 (18.8)

2 (5.7)

8 (13.3)

.468

Smoking, n(%)

215 (48.9)

127 (49.2)

27 (49.1)

18 (56.2)

14 (40.0)

29 (48.3)

.769

Drinking, n(%)

179 (40.7)

108 (41.9)

22 (40.0)

16 (50.0)

10 (28.6)

23 (38.3)

.467

TOAST, n(%)

      

.008

Large-artery atherosclerosis

293 (66.6)

187 (72.5)

29 (52.7)

21 (65.6)

21 (60.0)

35 (58.3)

 

Cardioembolism

58 (13.2)

34 (13.2)

11 (20.0)

4 (12.5)

2 (5.7)

7 (11.7)

 

Small-vessel occlusion

14 (3.2)

10 (3.9)

0 (0.0)

1 (3.1)

1 (2.9)

2 (3.3)

 

Stroke of other determined etiology

9 (2.0)

4 (1.6)

3 (5.5)

1 (3.1)

0 (0.0)

1 (1.7)

 

Stroke of undetermined etiology

66 (15.0)

23 (8.9)

12 (21.8)

5 (15.6)

11 (31.4)

15 (25.0)

 

Admission SBP (mmHg), median [IQR]

150 [136–166]

151 [137–166]

151 [130–160]

156 [141–166]

145 [130–165]

145 [135–170]

.804

Admission DBP (mmHg), median [IQR]

88 [78–96]

88 [79–96]

80 [74–93]

92 [89–98]

86 [79–95]

83 [75–94]

.294

  1. MT mechanical thrombectomy, tPA tissue plasminogen activator, DNT door-to-needle, NIHSS national institutes of health stroke scale, TOAST Trial of Org 10,172 in Acute Stroke Treatment, SBP systolic blood pressure, DBP diastolic blood pressure